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Pso diagnoses (ICD-9 codes: 696.1). One Pso-free patient (i.e., without Pso or psori-
atic arthritis diagnosis) was randomly selected to match each Pso patient by age
and gender. Patient demographic characteristics and comorbidity profile informa-
tion, including the Charlson comorbidity index (CCI) score, the prevalence of auto-
immune diseases, and an exhaustive list of other comorbidities were compared
between Pso and Pso-free patients using Wilcoxon signed rank tests or McNemar
tests. RESULTS: Among the 106,128 selected matched pairs, 52% were female and
the mean age was 52 years (SD15 years). In the Pso population, 77% had mild Pso
(i.e., patients who did not use any systemic therapies) and 23% had moderate-to-
severe Pso (i.e., patients receiving phototherapy, conventional systemic therapies,
or biologics). Pso patients had a higher mean CCI score compared to Pso-free pa-
tients (1.06 vs. 0.74; p.01). Compared to Pso-free patients, Pso patients had a
significantly higher prevalence of autoimmune diseases, including psoriatic arthri-
tis (10.2% vs. 0.0%), rheumatoid arthritis (5.4% vs.1.4%), ankylosing spondylitis
(1.5% vs. 0.8%), ulcerative colitis (1.0 vs. 0.5%), and Crohn’s disease (0.8% vs. 0.4%)
(all p.01). As shown in other studies, Pso patients also had higher prevalence of
other comorbidities, including hypertension (41.8% vs. 34.5%), chronic pulmonary
diseases (17.7% vs. 12.6%), diabetes (16.4% vs. 12.6%), hypothyroidism (12.0% vs.
9.0%), deficiency anemias (9.3% vs. 6.7%), valvular diseases (7.8% vs. 5.6%), solid
tumorwithoutmetastases (7.2% vs. 5.8%), psychoses (6.5% vs. 4.2%), and peripheral
vascular disease (6.4% vs. 4.3%) when compared to Pso-free patients (all p.01).
CONCLUSIONS: Psoriasis was associated with a substantial comorbidity burden,
including a significantly higher prevalence of autoimmune diseases and other
physical and mental comorbidities.
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OBJECTIVES: To compare efficacy of ustekinumab with other biologics using the
Psoriasis Area and Severity Index (PASI) in adult patients with moderate-to-severe
psoriasis in the induction phase. METHODS: A systematic literature review was
conducted for randomized controlled trials (RCTs) of biologics for moderate-to-
severe psoriasis. PASI 75 was used as the primary outcome. Bayesian mixed treat-
ment comparison (MTC) was employed by fitting three models-a fixed effect, a
random-effects, and a random-effects with meta-regression model. Sensitivity
analyses were conducted by including supra- and sub-therapeutic doses, by ex-
cluding studies with only biologic naïve patients, and by changing initial values for
Markov Chain Monte Carlo (MCMC) simulation. RESULTS: Seventeen studies were
selected. The random-effects model was the best fit for the data. For PASI 75, all
biologics were significantly more efficacious than placebo, with rank order: inflix-
imab (odds ratio (OR)155.70), ustekinumab (OR56.53), adalimumab (OR30.85),
etanercept (OR27.11), and alefacept (OR5.48). In the therapeutic class compari-
son, the IL-12/23 inhibitor (ustekinumab) had the highest odds of PASI 75 compared
to placebo (OR69.48), followed by TNF-Is (adalimumab, etanercept, and inflix-
imab) (OR42.22), and the T- cell inhibitor (alefacept) (OR5.63). In the pair-wise
comparison, ustekinumab appeared to have statistically significantly higher odds
of achieving the PASI 75 than adalimumab (OR1.84), alefacept (OR10.38), and
etanercept (OR 2.07), but a lower odds compared to infliximab (OR0.36).
CONCLUSIONS: Ustekinumab appeared to be more efficacious than adalimumab,
etanercept, and alefacept, but not infliximab. In the therapeutic class comparison,
the decreasing rank orders were anti-IL 12/23 agents, anti-TNF- agents and T-cell
targeted agents.
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OBJECTIVES:To compare the impact of 12weeks’ BTDS 20 andBTDS 5 treatment on
sleep among patients with moderate-to-severe chronic low back pain (CLBP), to
examine changes in the burden of CLBP on sleep with 12 weeks of BTDS use, and to
describe sleep outcomes over 12months of continued BTDS treatment.METHODS:
This post-hoc analysis used data from a double-blind (DB) randomized trial evalu-
ating BTDS 20 against BTDS 5 for treatment of opioid-experienced patients with
moderate-to-severe CLBP and its 12month open-label treatment extension. During
the course of BTDS treatment, patients completed the 12-item Medical Outcomes
Study Sleep Scale, which measures several sleep domains, including Disturbance
and overall Quality. ANCOVA models compared scores between treatment arms
during the 12-weekDBphase, and repeatedmeasuresmixed-models analysis com-
pared scores across visits during the 12-month treatment. Burden was examined
by comparing trial patients with an age- and gender-matched U.S. general popu-
lation sample (GPS) at trial baseline and DB endpoint. RESULTS: BTDS 20 patients
showed significantly less Disturbance and better overall Quality than BTDS 5 pa-
tients at week 12 DB (P0.05), an advantage that emerged by week 4. Analyses of
Disturbance and Quality scores across DB indicated statistically significant effects
for treatment (P 0.05), but not for visit or their interaction (P0.05). No reduction
from the end of DB Disturbance and Quality scores were observed following 12
months of BTDS 20 treatment. At baseline, patients’ Disturbance and Quality
scores were significantly worse than those of the GPS; by week 12 of the DB phase,
BTDS 20 patients’ average scores improved over the GPS, while BTDS 5 patients’ did
not. CONCLUSIONS: Moderate-to-severe CLBP patients receiving BTDS 20 exhib-
ited larger improvements in sleep Disturbance and Quality than those receiving
BTDS 5. Improvements in sleep were sustained during 12 months of continued
BTDS treatment.
PSY7
BLOOD TRANSFUSION MANAGEMENT IN ELECTIVE MAJOR ORTHOPAEDIC
SURGERY (MOS) IN FRANCE
Durupty D1, Deshaires L1, Mammar N2, Zakin L2, Lafuma A3
1clinique Arago, paris, paris, France, 2Vifor Pharma International, Neuilly-sur-Seine Cedex, Ile de
France, France, 3Cemka Eval, bourg la reine, hauts de seine, France
OBJECTIVES: To assess appropriateness of anemia management in order to opti-
mize BT during MO.METHODS:Hip (HA) and knee arthroplasty (KA) are frequently
associated with high volumes of blood loss. When those surgeries are elective, it is
possible, with adequate pre-operativemanagement, to decrease blood transfusion
(BT). A retrospective study was conducted in a single French centre on consecutive
cases of patients undergoing electiveMOS in 2009. Criteria to evaluate optimization
of BT were: transfusion rate, BT or no BT, according to international guidelines,
optimal BT rate according to potential adequate anemia treatment (ESA, oral or IV
iron) and administration of tranexanic acid. RESULTS: Sixty cases of MOS patients
were included with 38 females and 22males. 40 and 19 patients had undergone HA
and KA, respectively. 55 patient charts were sufficiently documented to be evalu-
able. The mean delay for pre-operative consult was 32 days with a minimum of 5
days. According to hemoglobin value recorded and potential blood loss estimated
during this visit, it was possible to predict that (in the absence of pharmacological
treatment) 18 patients over 55 would be transfused during surgery. Among the 37
patients with no predictable BT, 3 were nevertheless transfused. Among the 18
patients with predictable BT, 14 were not transfused (10 were treated with ESA and
14 with IV iron) and 4 patients (not treated with ESA or iron) transfused.
CONCLUSIONS: Anemia management before MOS could decrease BT during hos-
pitalisation. Currentmedical practice assessment in a single French centre showed
that in 32% of the patients anemia should be treated prior to hospitalisation.
Among these patients, one out of 5 was not adequately treated with ESA and/or
iron and was finally transfused. Approximately half of the BT could be avoided in
this centre, which has already a low blood transfusion rate (13%).
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OBJECTIVES: In recent years, methodologies used in outcomes research have ad-
vanced. In a field where many disciplines, such as clinicians, epidemiologists,
economists and statisticians interact frequently, a tool to communicate informa-
tion clearly and effectively through graphical means has become a necessity.To
present treatment patterns among patients diagnosed with ankylosing spondylitis
(AS) using data visualization techniques.METHODS:Using 100%nationalMedicare
data with Part D information, we selected patients over the age of 65 with at least
oneAS diagnosis.We identified patientswho initiated therapywith tumor necrosis
factor (TNF) and non-TNF agents. For 2 years after the initiation, we examined
switching to another TNF, a non-TNF, and discontinuation treatment patterns.
Using a processing language, we created a data visualization tool to demonstrate
changes in treatment patterns after the first and second switches. RESULTS:A total
of 1,159 AS patients (1,159) initiated therapy with TNF. 5.69% of these patients
switched to another TNF, 2.67% switched to a non-TNF, 55.91% discontinued ther-
apy and 35.72% continued their initial therapy. Among patients who switched to
another TNF, 53.03% remained on the switched therapy, 28.79% discontinued ther-
apy, 15.15% switched to another TNF, and 3.03% switched to a non-TNF. A total of
532 AS patients initiated therapy with a non-TNF. 1.50% of these patients switched
to a TNF, 0.94% switched to a non-TNF, 93.61% discontinued their therapy and
3.95% continued their initial therapy. CONCLUSIONS: Treatment patterns can be
difficult to present, especially when analyzing several years of data and various
drug switches. Data visualization tools can help present these complicated flows
effectively to researchers.
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OBJECTIVES: This retrospective cohort study evaluated the prevalence, character-
istics, healthcare resource utilization (HCRU) and costs of patients with diagnosed
opioid abuse (OpA) using administrative claims from the Thomson MarketScan
Commercial and Medicare Supplemental research databases (44.9 million lives).
METHODS: Patients aged 12 years with OpA (ICD-9-CM codes: 304.0, 304.7, 305.5,
965.0 excluding 965.01) during OCT2008–SEPT2009 were identified. OpAers (cases)
were randomly matched 1:3 on demographics and geographic region to controls
(no OpA); OpA date being the index date. Unadjusted all-cause HCRU and total
costs (inpatient, outpatient, emergency department (ED), and Rx) were calculated
for the 6-month period before (pre-index) and the 12-month period after the index
date (post-index). Opioid use was also examined during the pre-index period for
OpAers and controls. RESULTS: The overall prevalence of OpA was 0.12% (average
age 41.9 years). Among OpAers, 68% had prescriptions for opioids. Among OpAers
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using opioids, 44% used short-acting, 19% long-acting, and 37% both. Prevalence of
OpA among those with a history of opioid use was 0.56% compared to 0.06% in
non-users (p0.0001). All HCRU was significantly greater for the pre-index and
post-index periods for OpAers compared to controls (p0.0001). Total health care
costs were greater for OpAers compared with controls; $11,13726,677 versus
$2,2318,438 (p0.0001) in the pre-index and $25,65454,928 vs. $4,90218,682
(p0.0001) in the post-index periods, respectively. Prescription opioid costs for
OpAers and controls was $1,9356844 and $34486 (p0.0001), respectively.
Among OpAers, total healthcare costs were greater for those with pre-index opioid
use compared with those without pre-index opioid use; $13,92030,012 versus
$5,22216,073 (p0.0001) in the pre-index and $29,50056,713 versus
$17,48149,960 (p0.0001) in the post-index periods. CONCLUSIONS: OpAers have
significantly greater HCRU and total cost before and after OpA compared to
matched controls. OpAerswith opioid use had significantly greater total cost before
and after OpA than OpAers without opioid use.
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OBJECTIVES: To identify the incidence and prevalence of idiopathic inflammatory
myopathies (IIMs) among commercially insured and Medicare and Medicaid en-
rolled populations in theUS, using administrative claims data. IIMs are a rare group
of autoimmune syndromes characterized by chronic muscle inflammation and
muscle weakness with no known cause. Little is known about their incidence and
prevalence.METHODS:Medical claims with an IIM diagnosis (ICD-9-CM 710.3 [der-
matomyositis (DM)], 710.4 [polymyositis (PM)], 728.81[interstitial myositis]) were
retrospectively examined in the MarketScan® databases to identify age- and gen-
der-adjusted annual IIM incidence and prevalence for 2004-2008. Sensitivity anal-
ysis was performed for evidence of a specialist visit (rheumatologist/ neurologist/
dermatologist), systemic corticosteroid or immunosuppressant use, or muscle
biopsy. RESULTS: A total of 2990 incident patients between 2004 and 2008 (67%
female, 17% Medicaid enrollees, 27% aged 65 years) were identified. Overall ad-
justed IIM incidence for 2004-2008 for commercial and Medicare supplemental
groups combined were 4.27 cases (95% CI, 4.09-4.44) and for Medicaid, 5.23 (95% CI
4.74-5.72) per 100,000 person-years (py). Disease sub-type incidence rates per
100,000-py were 1.52 (95% CI 1.42-1.63) and 1.70 (1.42-1.97) for DM, 2.46 (2.33-2.59)
and 3.53 (3.13-3.94) for PM, and 0.73 (0.66-0.81) and 0.78 (0.58-0.97) for interstitial
myositis for the commercial/Medicare and Medicaid cohorts respectively. Annual
incidence fluctuated over time with the base MarketScan populations. There were
7,155 prevalent patients, with annual prevalence ranging from 20.62 to 25.32 per
100,000 for commercial/Medicare (83% of prevalent cases) and from 15.35 to 32.74
for Medicaid. Sensitivity analysis reduced the incidence rates and prevalence by
20-40%. CONCLUSIONS: This study found higher IIM incidence and prevalence
than historical small population based reports. Employer turnover, miscoding and
misdiagnosing, care seeking behavior, and fluctuations in database membership
over time can influence the results. Further studies are needed to confirm the
incidence and prevalence of IIMs in the US population.
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OBJECTIVES: Modifiable risk factors in the US workforce have been documented
previously, but knowledge of behavioral risk factor prevalence among working
adults remains incomplete. Toassess currentnational estimates for smoking,heavier
alcohol consumption, obesity, insufficient exercise and fair/poor health status for
working adults aged 20 years and older.METHODS: Analysis of nationally represen-
tative data collected from employed adults 20 years and older participating in the
National Health Interview Survey (NHIS) 2010 (aged 20 to 64 years, n 13,844, aged
20 to 39 years, n6,495, aged 40 to 64 years, n7,349, men aged 20 to 64 years 
6,825, women aged 20 to 64 years  7,019). RESULTS: The prevalence of current
smoking amongworking adults aged 20 to 64 years is 19.6%; younger workers (aged
20 to 39 years) have a significantly higher prevalence of current smoking than
workers 40 to 64 years, (21.2% vs. 18.3%, p0.001) and employed men have a sig-
nificantly higher smoking prevalence than employed women (21.4% vs. 17.6%, re-
spectively, p0.0001). An estimated 5.7% and 5.5% of working men and women,
respectively, report heavier alcohol consumption (p0.5573, 2 drinks/day for men,
1 drink/day forwomen). The prevalence of insufficient exercise is equivalent among
working men and women, 30.6% and 31.0%, respectively. Obesity prevalence in the
workforce is 33.5%; obesity rates are 31.6% and 35.1% among workers 20 to 39 years
and 40 to 64 years, respectively (p0.2665). Employed women and men are equally
likely to report that their health is fair/poor (6.0% vs. 5.1%). CONCLUSIONS: Current
smoking, insufficient exercise and obesity are prevalent in the US workforce. Ef-
fective workplace approaches including increased dissemination of educational
information are needed to reduce the burden of these risk factors.
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OBJECTIVES: Tapentadol ER is a new oral analgesic that has been shown to have a
lower incidence of gastrointestinal adverse events (AEs) than oxycodone CR at
equianalgesic doses.We estimated the annual budget impact of placing tapentadol
ER on a health plan formulary of long-acting opioids (LAOs) used to treat moderate
to severe chronic pain. METHODS: An Excel-based budget impact model was de-
veloped to estimate the annual direct healthcare costs associated with long-acting
formulations of tapentadol, oxycodone, morphine, hydromorphone, oxymor-
phone, and fentanyl. Costs included medications, copayments, AE management
and opioid switching/discontinuation. Incidence/prevalence estimates, AEs and
pain management resources and costs (medications, physician phone calls, office
visits, emergency room visits and hospitalizations) were based on published
sources. Drug costswere based onwholesale acquisition cost. All costswere in 2010
US dollars. Weighted-average daily drug consumption (DACON) and formulary
sharewere obtained from IMSHealth. Base case analysis assumed a 10% formulary
share of tapentadol ERwith a 10% decrease of oxycodone CR. Results are presented
as the per-member per-month (PMPM) cost difference after adding tapentadol ER to
the formulary. RESULTS: In a health plan of 500,000 members, 2,600 (0.52%) would
be expected to experience chronic pain annually and be treated with an LAO for an
average of 180 days. Adding tapentadol ER to the formulary (10% share) decreased
both pharmacy (-$0.0136 PMPM) andmedical (-$0.0008 PMPM) costs as well as total
costs (-$0.0144 PMPM), with annual budget savings of $85,992. This was driven by
lower DACON and lower incidence of AEswith tapentadol ER versus oxycodone CR,
leading to reduced resource use and costs. In sensitivity analysis, resultsweremost
sensitive to drug acquisition costs. CONCLUSIONS: Results suggest that increasing
market share of tapentadol ER while reducing oxycodone CR would decrease a
health plan’s budget by decreasing both pharmacy and medical costs.
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OBJECTIVES: Illustrate potential budgetary impact of a risk-share agreement in a
US health plan using a case study of certolizumab pegol (CZP) as treatment for
moderate to severe rheumatoid arthritis (RA).METHODS: An economic model was
developed to evaluate the budget impact to a hypothetical 50 million member
health plan of adding CZP to a formulary. The target population was patients naïve
to TNF inhibitors. Model comparators included adalimumab, etanercept, inflix-
imab, and golimumab. Comparable efficacy is assumed across therapies; discon-
tinuation rates were assumed to differ by therapy, as evidenced by claims data.
Model parameters were estimated using published data, market research, and an
administrative claims database analysis. The base-case included a risk-share com-
ponent for which the health plan received a rebate for clinically non-responsive
CZP patients at week 12. Non-responsive CZP patients were assumed to receive an
alternative TNF-alpha inhibitor for the remainder of the 3-year model horizon.
Analyses captured differences in drug acquisition and intravenous administration
costs for the base-case and an alternate scenario assuming no risk-share agree-
ment. Deterministic sensitivity analyseswere also conducted.RESULTS:Assuming
a risk-share agreement, per-patient per-month (PPPM) savings in years 1, 2, and 3
were $4.22, $2.26, and $2.26, respectively. Applied to a hypothetical health-plan of
50 million members, annual cost savings are $3.6M, $2M, and $2.1M in years 1, 2,
and 3, respectively. Without a risk-share agreement, PPPM savings were $3.27 in
year 1 and $2.21 in years 2 and 3. Model results were most sensitive to average
monthly pharmacy costs of CZP and infliximab. CONCLUSIONS: The analysis sug-
gests that under a risk-share agreement, the addition of CZP to a US health plan
formulary may result in cost savings to the plan. Additionally, even without a
risk-share agreement, the addition of CZP may provide cost savings.
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OBJECTIVES: This study aimed to compare direct healthcare costs and opioid use
over a 1-year period following initiation with duloxetine versus other standard of
care (SOC) treatments among patients with chronic low back pain (CLBP).
METHODS: This retrospective cohort study assessed commercially-insured Mar-
ketscan CLBP patients aged 18-64 years who initiated duloxetine or other treat-
ments (tricyclic antidepressants, venlafaxine, pregabalin, gabapentin, muscle re-
laxants and opioids) in 2009. The first dispense date was defined as the index date.
Selected patientswere required to have at least two lowback pain (LBP) inpatient or
outpatient claims with at least 90 days gap between the 2 in the 12-month pre-
index period. Both duloxetine and SOC cohorts were then matched via propensity
scoring (n668 for each cohort), controlling for demographics, comorbidities, prior
healthcare utilization and costs, and prior medication history. Health care costs
and opioid use (among patients not initiated on opioids) over the 12-month post-
index period were compared between cohorts. RESULTS: Total health care costs
over the 12-month post-index period were $17,435 among duloxetine-initiated pa-
tients, versus $19,633 (p0.1781) for SOC-initiated patients. Duloxetine-initiated
patients also had significantly lower inpatient costs ($3,486 vs. $5,975, p0.0219).
While both groups had similar outpatient costs ($9,558 vs. $10,424, p0.3324),
CLBP-related outpatient costs were significantly lower among duloxetine-initiated
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